Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TRX518 |
Synonyms | |
Therapy Description |
TRX518 is an activating monoclonal antibody to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), that blocks GITR signaling, leading to activation of immune response (PMID: 31036879). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TRX518 | TRX-518|TRX 518 | GITR Antibody 7 | TRX518 is an activating monoclonal antibody to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), that blocks GITR signaling, leading to activation of immune response (PMID: 31036879). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02628574 | Phase I | TRX518 | Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors | Completed | USA | 0 |
NCT01239134 | Phase I | TRX518 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors | Completed | USA | 0 |